Barinthus Biotherapeutics (BRNS) Receivables (2020 - 2024)
Barinthus Biotherapeutics' (BRNS) quarterly Receivables came in at $7.1 million in Q4 2024, up 45.46% YoY from $4.9 million in Q1 2024, and up 37.39% on a QoQ basis from $5.2 million in Q1 2024.
Barinthus Biotherapeutics (BRNS) Receivables (2020 - 2024) Analysis & Trends
Barinthus Biotherapeutics (BRNS) has 5 years of Receivables data on file, last reported at $7.1 million in Q4 2024.
- Quarterly Receivables rose 45.46% year-over-year to $7.1 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $7.1 million (up 45.46% YoY) and the FY2024 annual result came in at $7.1 million, up 45.46% from the prior year.
- Receivables grew to $7.1 million in Q4 2024, from $5.2 million in the prior quarter.
- In the past five years, Receivables ranged from a high of $22.8 million in Q1 2022 to a low of $2.7 million in Q1 2023.
- A 5-year average of $6.9 million and a median of $5.3 million in 2021 frame the typical range for Receivables.
- Annual changes were most pronounced in 2022 — Receivables jumped 469.3% — and 2023, when it slumped 88.27%.
- Tracing BRNS's Receivables over 5 years: stood at $3.2 million in 2020, then jumped by 93.71% to $6.2 million in 2021, then surged by 61.07% to $10.1 million in 2022, then sank by 51.24% to $4.9 million in 2023, then jumped by 45.46% to $7.1 million in 2024.
- The last three Receivables figures came in at $7.1 million (Q4 2024), $5.2 million (Q1 2024), and $4.9 million (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.29 Bn | 131.44 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 59.49 Bn | 54.36 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 42.02 Bn | 36.92 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 30.79 Bn | 27.48 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 28.26 Bn | 9.87 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.30 Bn | 26.14 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.10 Bn | 26.26 Bn | - | - |
| 10 | Barinthus Biotherapeutics | 25.73 Mn | 25.73 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 7.14 Mn |
| Mar 31, 2024 | 5.20 Mn |
| Dec 31, 2023 | 4.91 Mn |
| Mar 31, 2023 | 2.67 Mn |
| Dec 31, 2022 | 10.07 Mn |
| Sep 30, 2022 | 6.18 Mn |
| Mar 31, 2022 | 22.79 Mn |
| Dec 31, 2021 | 6.25 Mn |
| Sep 30, 2021 | 5.42 Mn |
| Jun 30, 2021 | 4.60 Mn |
| Mar 31, 2021 | 4.00 Mn |
| Dec 31, 2020 | 3.23 Mn |